PCSK9 and infection: In previous genome-editing studies, rAAV was administered at a high dose in animals by using AAV::CRISPR-SaCas9: Ran et al. administered rAAV9 at 2 × 1011 v.g./mouse in their investigation of the use of rAAV9::SaCas9-gRNA to target the mouse PCSK9 gene(15); and Kaminski et al. used rAAV9::SaCas9-gRNA to inhibit the expression of HIV in HIV Tg26 transgenic mice by injecting the virus at 1012 multiplicity of infection/mouse, twice with a 5-day interval (16).